Synaptogenix, Inc. Changes Certifying Accountant

TL;DR

Synaptogenix switched accountants as of Sept 30. Old name was Neurotrope Bioscience.

AI Summary

Synaptogenix, Inc. filed an 8-K on October 4, 2024, reporting a change in its certifying accountant as of September 30, 2024. The company previously operated under the name Neurotrope Bioscience, Inc. before changing its name on March 12, 2013.

Why It Matters

A change in a company's auditor can sometimes signal underlying financial concerns or a desire for a fresh perspective on financial reporting.

Risk Assessment

Risk Level: low — This filing solely reports a change in the company's accountant, which is a routine administrative event.

Key Players & Entities

• Synaptogenix, Inc. (company) — Registrant
• September 30, 2024 (date) — Date of earliest event reported
• October 4, 2024 (date) — Date of report
• Neurotrope Bioscience, Inc. (company) — Former company name
• March 12, 2013 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share SNPX The Nasdaq

Filing Documents

• tm2425569d1_8k.htm (8-K) — 28KB
• tm2425569d1_ex16-1.htm (EX-16.1) — 3KB
• tm2425569d1_img001.jpg (GRAPHIC) — 10KB
• tm2425569d1_img002.jpg (GRAPHIC) — 3KB
• 0001104659-24-106284.txt ( ) — 222KB
• snpx-20240930.xsd (EX-101.SCH) — 3KB
• snpx-20240930_lab.xml (EX-101.LAB) — 33KB
• snpx-20240930_pre.xml (EX-101.PRE) — 22KB
• tm2425569d1_8k_htm.xml (XML) — 4KB

01. Changes in Registrant's Certifying Accountant

Item 4.01. Changes in Registrant's Certifying Accountant. Resignation of Independent Registered Public Accounting Firm On September 30, 2024, in conjunction with its exit from providing audit services to publicly traded companies, Morison Cogen LLP ("Morison Cogen") resigned from its role as independent registered public accounting firm for Synaptogenix, Inc. (the "Company"). Morison Cogen's reports on the Company's consolidated financial of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the fiscal years ended December 31, 2023 and December 31, 2022 and the subsequent interim period through September 30, 2024, (i) there were no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K, between the Company and Morison Cogen on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, any of which that, if not resolved to Morison Cogen's satisfaction, would have caused Morison Cogen to make reference to the subject matter of any such disagreement in connection with its reports for such years and interim period, and (ii) there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K. The Company provided Morison Cogen with a copy of the above disclosures and requested that Morison Cogen furnish a letter addressed to the Securities and Exchange Commission stating whether it agrees with the Form 8-K. Newly Engaged Independent Registered Public Accounting Firm On October 4, 2024, the Company engaged Stephano Slack LLC ("Stephano Slack") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 202

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits – The following exhibits are filed as part of this report: Exhibit No. Description of Exhibit 16.1 Letter from Morison Cogen LLP addressed to the Securities and Exchange Commission dated October 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNAPTOGENIX, INC. Date: October 4, 2024 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR